Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Sep 19, 2026

Active, not recruiting

Biomarkers for Predicting Response to PD-1 Inhibitor Therapy in Squamous Cell Carcinoma: A Retrospective-Prospective Cohort Study

Sep 16, 2026

Recruiting

Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node, a Prospective, Multicenter, Non-inferior Randomized Controlled Trial

Earlier

Sep 1, 2026TrialAn Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Participants With Advanced Hepatitis B Virus Related Hepatocellular Carcinoma

Aug 29, 2026TrialAn Open-label, Single-center Study to Evaluate the Dose Escalation and Cohort Expansion of YSCH-01 in Subjects With Pulmonary Metastasis of Advanced Solid Tumors and Advanced Non-small Cell Lung Cancer by Nebulized Inhalation Administration

Aug 29, 2026TrialA Phase II Open-label Clinical Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Patients With Relapsed/Refractory Lymphoma

Aug 29, 2026TrialInduction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy (IDEAL-RT) in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Multicenter, Prospective, Phase II, Randomized Non-Inferiority Controlled Trial

Aug 21, 2026TrialTislelizumab Plus Dose-Dense P-GemOx and Radiation Therapy for Early-Stage Intermediate/High-Risk Extranodal NK/T-Cell Lymphoma: A Multicenter Phase II Trial

Aug 20, 2026TrialEstablishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study

3 more events

Aug 19, 2026TrialPaclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）

Aug 19, 2026TrialSacituzumab Tirumotecan Monotherapy or Combination Therapy in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-Negative Breast Cancer: A Real-World Study

Aug 13, 2026TrialClinical Utility Evaluation of a Surgical Sequencing Decision-Support Software in Simulated Cases of Colorectal Liver Metastases: A Multicenter Prospective Study (COLORS-Validate Study)

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)